KR20020061646A - 아다만탄 유도체 - Google Patents
아다만탄 유도체 Download PDFInfo
- Publication number
- KR20020061646A KR20020061646A KR1020027007702A KR20027007702A KR20020061646A KR 20020061646 A KR20020061646 A KR 20020061646A KR 1020027007702 A KR1020027007702 A KR 1020027007702A KR 20027007702 A KR20027007702 A KR 20027007702A KR 20020061646 A KR20020061646 A KR 20020061646A
- Authority
- KR
- South Korea
- Prior art keywords
- tricyclo
- ylmethyl
- dec
- propyl
- benzamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/61—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms not forming part of a nitro radical, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
- C07C2603/74—Adamantanes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
Abstract
Description
Claims (22)
- 하기 화학식 I의 화합물 또는 그의 제약상 허용되는 염 또는 용매화물.<화학식 I>상기 식에서,D는 CH2또는 CH2CH2를 나타내고,E는 C(O)NH 또는 NHC(O)를 나타내고,R1및 R2는 각각 독립적으로 수소, 할로겐, 아미노, 니트로, C1-C6알킬 또는 트리플루오로메틸을 나타내지만, R1및 R2둘다가 동시에 수소를 나타낼 수 없고,R3은 하기 화학식 II의 기를 나타내고,<화학식 II>R4는 C1-C6알킬기를 나타내고,X는 산소 또는 황 원자 또는 NR13, SO 또는 SO2기를 나타내고,R5는 수소를 나타내거나, 또는 R5는 C1-C6알킬 또는 C2-C6알케닐을 나타내는데, 각각은 할로겐, 히드록실, (디)-C1-C6-알킬아미노, -Y-R6,, 및 질소, 산소 및 황으로부터 독립적으로 선택된 1 내지 4 개의 헤테로원자를 포함하는 5원 또는 6원 헤테로방향족 고리로부터 선택된 하나 이상의 치환기에 의해 임의로 치환될 수 있고, 여기서 헤테로방향족 고리는 할로겐, 히드록실 및 C1-C6알킬로부터 선택된 하나 이상의 치환기에 의해 임의로 치환될 수 있으며,Y는 산소 또는 황 원자 또는 NH, SO 또는 SO2기를 나타내고,R6은 -R7Z 기를 나타내는데, R7은 C2-C6알킬기를 나타내고 Z는 -OH, -CO2H, -NR8R9, -C(O)NR10R11또는 -N(R12)C(O)-C1-C6알킬기를 나타내고, Y가 산소 또는 황 원자 또는 NH 기를 나타내는 경우에, R6은 추가로 수소, C1-C6알킬, C1-C6알킬카르보닐, C1-C6알콕시카르보닐, -C(O)NR14R15, -CH2OC(O)R16, -CH2OC(O)OR17또는 -C(O)OCH2OR18을 나타내고,R8, R9, R10, R11및 R12는 각각 독립적으로 수소 원자 또는 C1-C6알킬기를 나타내고,R13은 수소, C3-C8시클로알킬, C3-C8시클로알킬메틸을 나타내거나, 또는 R13은 히드록실 및 C1-C6알콕시로부터 선택된 하나 이상의 치환기에 의해 임의로 치환된 C1-C6알킬기를 나타내고, 및R14, R15, R16, R17및 R18은 각각 독립적으로 C1-C6알킬기를 나타내나, 단, E가 C(O)NH이고, X가 O, NH 또는 N(C1-C6알킬)인 경우, R5는 수소 원자 또는 비치환된 C1-C6알킬기외에 다른 것이다.
- 제1항에 있어서, D가 CH2를 나타내는 화합물.
- 제1항 또는 제2항에 있어서, E가 NHC(O)를 나타내는 화합물.
- 제1항 내지 제3항 중 어느 한 항에 있어서, R1및 R2가 각각 독립적으로 수소, 염소 또는 브롬 원자, 또는 아미노, 니트로, C1-C6알킬 또는 트리플루오로메틸기를 나타내는 화합물.
- 제1항 내지 제4항 중 어느 한 항에 있어서, X가 산소 원자 또는 NR13기를 나타내는 화합물.
- 제5항에 있어서, R13이 수소, -(CH2)2OH, 메틸, 에틸, n-프로필, 이소프로필, n-부틸, n-펜틸, n-헥실, 시클로프로필, 시클로펜틸, 시클로헥실 또는 시클로헥실메틸을 나타내는 화합물.
- 제1항 내지 제6항 중 어느 한 항에 있어서, R5가 하나의 치환기 -Y-R6으로 치환된 C1-C6알킬기를 나타내는 화합물.
- 제1항 내지 제7항 중 어느 한 항에 있어서, Y가 산소 또는 황원자 또는 NH 기를 나타내는 화합물.
- 제8항에 있어서, R6이 -(CH2)2OH, -(CH2)3OH, 수소, 메틸, 이소프로필, 메틸카르보닐 또는 t-부틸카르보닐을 나타내는 화합물.
- 제1항에 있어서, 하기의 화합물로부터 선택되는 화학식 I의 화합물, 또는 그의 제약상 허용되는 염 또는 용매화물:2-클로로-5-[[2-(2-히드록시-에틸아미노)-에틸아미노]-메틸]-N-(트리시클로 [3.3.1.13,7]데크-1-일메틸)-벤즈아미드,2-클로로-5-[[2-(2-히드록시에톡시)에틸아미노]메틸]-N-(트리시클로[3.3.1.13,7] 데크-1-일메틸)-벤즈아미드,2-클로로-5-[(3-히드록시-2,2-디메틸프로필아미노)메틸]-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드,2-클로로-5-[(5-히드록시펜틸아미노)메틸]-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드,2-클로로-5-[[2-[(2-히드록시에틸티오)에틸아미노]메틸]-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드,2-클로로-5-[3-[(2-히드록시에틸)아미노]프로필]-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드,2-클로로-5-[3-[(3-히드록시프로필)아미노]프로필]-N-(트리시클로[3.3.1.13,7]-데크-1-일메틸)-벤즈아미드,2-클로로-5-[3-(메틸아미노)프로필]-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드,2-클로로-5-[3-[(l-메틸에틸)아미노]프로필]-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드,5-[3-[(2-아미노-2-메틸프로필)아미노]프로필]-2-클로로-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드,2-클로로-5-[3-[(4-히드록시부틸)아미노]프로필]-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드,2-클로로-5-[3-[(2-히드록시-2-메틸프로필)아미노]프로필]-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드,2-클로로-5-[3-[[2-(메틸아미노)에틸]아미노]프로필]-N-(트리시클로[3.3.1.13,7]데크-1- 일메틸)-벤즈아미드, 이염산염,(S)-2-클로로-5-[3-[(2-히드록시프로필)아미노]프로필]-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드, 염산염,(R)-2-클로로-5-[3-[(2-히드록시프로필)아미노]프로필]-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드, 염산염,(R)-2-클로로-5-[3-[(2-히드록시-1-메틸에틸)아미노]프로필]-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드, 염산염,2-클로로-5-[3-[[2-히드록시-1-(히드록시메틸)-1-메틸에틸]아미노]프로필]-N (트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드,5-[3-[[2-(아세틸아미노)에틸]아미노]프로필]-2-클로로-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드, 염산염,2-클로로-5-[3-[[2-(디에틸아미노)에틸]아미노]프로필]-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드, 이염산염,2-클로로-5-[3-[(3-메톡시프로필)아미노]프로필]-N-(트리시클로 [3.3.1.13,7] 데크-1-일메틸)-벤즈아미드, 염산염,2-클로로-5-[3-[(3-히드록시-3-메틸부틸)아미노]프로필]-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드, 염산염,2-클로로-5-[3-[(2-메톡시에틸)아미노]프로필]-N-(트리시클로[3.3.1.13,7]데크-1- 일메틸)-벤즈아미드, 염산염,2-클로로-5-[[3-(메틸아미노)프로폭시]메틸]-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드,2-클로로-5-[[2-[(2-히드록시에틸)아미노]에톡시]메틸]-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드, 아세트산염,2-클로로-5-[[2-[(3-히드록시프로필)아미노]에톡시]메틸]-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드, 아세트산염,2-클로로-5-[[[3-[(1-메틸에틸)아미노]프로필]아미노]메틸]-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드,5-[[(3-아미노프로필)아미노]메틸]-2-클로로-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드,2-클로로-5-[[[2-[(1-메틸에틸)아미노]에틸]아미노]메틸]-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드,3-[[3-[4-클로로-3-[[(트리시클로[3.3.1.13,7]데크-1-일메틸)아미노]카르보닐]페닐]프로필]아미노]프로판산, 2,2-디메틸프로필 에스테르, 트리플루오로아세트산염,5-(2-아미노에틸)-2-클로로-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드,2-클로로-5-[3-[(2-히드록시에틸)펜틸아미노]프로필]-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드,2-클로로-5-[3-(메틸-2-프로페닐아미노)프로필]-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드,2-클로로-5-[3-[[2-(디메틸아미노)에틸]메틸아미노]프로필]-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드,5-[3-(부틸에틸아미노)프로필]-2-클로로-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드,2-클로로-5-[3-(메틸펜틸아미노)프로필]-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드,2-클로로-5-[3-[[2-(디에틸아미노)에틸]에틸아미노]프로필]-N-(트리시클로 [3.3.1.13,7]데크-1-일메틸)-벤즈아미드,2-클로로-5-[3-[(2-히드록시에틸)메틸아미노]프로필]-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드,2-클로로-5-[3-(디프로필아미노)프로필]-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드,2-클로로-5-[3-[(2-히드록시에틸)(1-메틸에틸)아미노]프로필]-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드,5-[3-[부틸(2-히드록시에틸)아미노]프로필]-2-클로로-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드,2-클로로-5-[3-(디에틸아미노)프로필]-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드,2-클로로-5-[3-(디메틸아미노)프로필]-N-(트리시클로[3.3.1.13.7]데크-1-일메틸)-벤즈아미드,5-[3-(부틸메틸아미노)프로필]-2-클로로-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드,2-클로로-5-[3-[(2-히드록시에틸)프로필아미노]프로필]-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드,2-클로로-5-[3-[에틸(2-히드록시에틸)아미노]프로필]-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드,2-클로로-5-[3-(디부틸아미노)프로필]-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드,2-클로로-5-[3-(에틸프로필아미노)프로필]-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드,2-클로로-5-[3-[메틸(l-메틸에틸)아미노]프로필]-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드,2-클로로-5[3-[[3-(디메틸아미노)프로필]메틸아미노]프로필]-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드,2-클로로-5-[3-[시클로헥실(2-히드록시에틸)아미노]프로필]-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드,2-클로로-5-[3-(시클로헥실메틸아미노)프로필]-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드,2-클로로-5-[3-(시클로헥실아미노)프로필]-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드,2-클로로-5-[3-[[l-(히드록시메틸)-2,2-디메틸프로필]아미노]프로필]-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드,2-클로로-5-[3-(시클로프로필아미노)프로필]-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드,2-클로로-5-[3-[[2-(디메틸아미노)에틸]아미노]프로필]-N-(트리시클로[3.3.1.13.7]데크-l-일메틸)-벤즈아미드,2-클로로-5-[3-[(3-히드록시-2,2-디메틸프로필)아미노]프로필]-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드,2-클로로-5-[3-[(1,1-디메틸에틸)아미노]프로필]-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드,2-클로로-5[3-[[3-(디메틸아미노)프로필]아미노]프로필]-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드,2-클로로-5-[3-(시클로펜틸아미노)프로필]-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드,2-클로로-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-5-[3-[(1,2,2-트리메틸프로필)아미노]프로필]-벤즈아미드,5-[3-(부틸아미노)프로필]-2-클로로-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드,2-클로로-5-[3-[[1-(히드록시메틸)-2-메틸프로필]아미노]프로필]-N-(트리시클로[3.3.1.13,7]데크-l-일메틸)-벤즈아미드,2-클로로-5-[3-[(1-메틸프로필)아미노]프로필]-N-(트리시클로 [3.3.1.13,7]데크-1-일메틸)-벤즈아미드,2-클로로-5-[3-[[2-(메틸티오)에틸]아미노]프로필]-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드,2-클로로-5-[3-[(2-히드록시-1,1-디메틸에틸)아미노]프로필]-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드,2-클로로-5-[3-[(시클로헥실메틸)아미노]프로필]-N-(트리시클로[3.3.1.13,7]데크-1- 일메틸)-벤즈아미드,2-클로로-5-[3-(2-프로페닐아미노)프로필]-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드,2-클로로-5-[3-[(2-플루오로에틸)아미노]프로필]-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드,2-클로로-5-[3-[(2-메톡시-1-메틸에틸)아미노]프로필]-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드,2-클로로-5-[3-[3-(메틸아미노)프로폭시]프로필]-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드, 이염산염,5-[[[(1-아미노시클로프로필)메틸](2-히드록시에틸)아미노]메틸]-2-클로로-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드,5-[[(2-히드록시에틸)[2-(메틸아미노)에틸]아미노]메틸]-2-메틸-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드,2-클로로-5-[3-[[2-(1-메틸-1H-이미다졸-4-일]에틸]아미노]프로필]-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드,2-클로로-5-[3-[[2-(1H-이미다졸-4-일)에틸]아미노]프로필]-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드,2-클로로-5-[3-[[3-(1H-이미다졸-1-일)프로필]아미노]프로필]-N-(트리시클로[3.3.1.13,7]데크-1-일메틸)-벤즈아미드.
- (a) X가 산소 또는 황 원자 또는 NR13기를 나타내는 경우, 하기 화학식 III의 화합물을 임의로, 적합한 은 염 존재하에 하기 화학식 IV의 화합물과 반응시키는 단계,(b) X가 SO 또는 SO2를 나타내는 경우, X가 황원자를 나타내는 화학식 I의 상응하는 화합물을 적절한 산화제와 반응시키는 단계, 또는(c) X가 NR13기를 나타내는 경우, 하기 화학식 V의 화합물을 환원제 존재하에 하기 화학식 VI의 화합물과 반응시키는 단계,및 임의로 (a), (b) 또는 (c) 단계 후에, 수득된 화학식 I의 화합물을 그의 제약상 허용되는 염 또는 용매화물로 전환하는 단계를 포함하는 제1항에 정의된 화학식 I의 화합물의 제조 방법:<화학식 III><화학식 IV><화학식 V><화학식 VI>상기 식에서,L1은 이탈기를 나타내고, X'는 산소 또는 황 원자 또는 NR13기를 나타내고, R20은 결합 또는 C1-C5알킬기를 나타내고, 및D, E, R1, R2, R4, R5및 R13은 화학식 I에 정의된 바와 같다.
- 제1항 내지 제10항 중 어느 한 항에 따른 화학식 I의 화합물, 또는 그의 제약상 허용되는 염 또는 용매화물을 제약상 허용되는 보조제, 희석제 또는 담체와 함께 포함하는 제약 조성물.
- 제1항 내지 제10항 중 어느 한 항에 따른 화학식 I의 화합물 또는 그의 제약상 허용되는 염 또는 용매화물을 제약상 허용되는 보조제, 희석제 또는 담체와 혼합하는 것을 포함하는, 제12항에 따른 제약 조성물의 제조 방법.
- 치료에 사용하기 위한 제1항 내지 제10항 중 어느 한 항에 따른 화학식 I의 화합물 또는 그의 제약상 허용되는 염 또는 용매화물.
- 류마티스성 관절염의 치료에 사용하기 위한 제1항 내지 제10항 중 어느 한 항에 따른 화학식 I의 화합물 또는 그의 제약상 허용되는 염 또는 용매화물.
- 만성 폐쇄성 폐질환의 치료에 사용하기 위한 제1항 내지 제10항 중 어느 한 항에 따른 화학식 I의 화합물 또는 그의 제약상 허용되는 염 또는 용매화물.
- 치료에 사용하기 위한 의약의 제조에 있어서 제1항 내지 제10항 중 어느 한 항에 따른 화학식 I의 화합물 또는 그의 제약상 허용되는 염 또는 용매화물의 용도.
- 류마티스성 관절염의 치료에 사용하기 위한 의약의 제조에 있어서 제1항 내지 제10항 중 어느 한 항에 따른 화학식 I의 화합물 또는 그의 제약상 허용되는 염 또는 용매화물의 용도.
- 만성 폐쇄성 폐질환의 치료에 사용하기 위한 의약의 제조에 있어서 제1항 내지 제10항 중 어느 한 항에 따른 화학식 I의 화합물 또는 그의 제약상 허용되는 염 또는 용매화물의 용도.
- 제1항 내지 제10항 중 어느 한 항에 따른 화학식 I의 화합물 또는 그의 제약상 허용되는 염 또는 용매화물의 치료 유효량을 필요한 환자에게 투여하는 것을 포함하는 면역 억제 방법.
- 제1항 내지 제10항 중 어느 한 항에 따른 화학식 I의 화합물 또는 그의 제약상 허용되는 염 또는 용매화물의 치료 유효량을 필요한 환자에게 투여하는 것을 포함하는 류마티스성 관절염의 치료 방법.
- 제1항 내지 제10항 중 어느 한 항에 따른 화학식 I의 화합물 또는 그의 제약상 허용되는 염 또는 용매화물의 치료 유효량을 필요한 환자에게 투여하는 것을 포함하는 만성 폐쇄성 폐질환의 치료 방법.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9904651A SE9904651D0 (sv) | 1999-12-17 | 1999-12-17 | Novel compounds |
SE9904651-8 | 1999-12-17 | ||
GB0015744A GB0015744D0 (en) | 2000-06-27 | 2000-06-27 | Novel compounds |
GB0015744.6 | 2000-06-27 | ||
GB0017942A GB0017942D0 (en) | 2000-07-22 | 2000-07-22 | Novel compounds |
GB0017942.4 | 2000-07-22 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020077000596A Division KR20070012883A (ko) | 1999-12-17 | 2000-12-12 | 아다만탄 유도체를 함유하는 제약 조성물 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20020061646A true KR20020061646A (ko) | 2002-07-24 |
KR100710110B1 KR100710110B1 (ko) | 2007-04-20 |
Family
ID=27255782
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020077000596A KR20070012883A (ko) | 1999-12-17 | 2000-12-12 | 아다만탄 유도체를 함유하는 제약 조성물 |
KR1020027007702A KR100710110B1 (ko) | 1999-12-17 | 2000-12-12 | 아다만탄 유도체 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020077000596A KR20070012883A (ko) | 1999-12-17 | 2000-12-12 | 아다만탄 유도체를 함유하는 제약 조성물 |
Country Status (32)
Country | Link |
---|---|
US (5) | US6881754B2 (ko) |
EP (5) | EP1352895B1 (ko) |
JP (2) | JP3710418B2 (ko) |
KR (2) | KR20070012883A (ko) |
CN (1) | CN1312120C (ko) |
AR (1) | AR035325A1 (ko) |
AT (4) | ATE350364T1 (ko) |
AU (2) | AU780506B2 (ko) |
BR (1) | BRPI0016395B8 (ko) |
CA (1) | CA2393352C (ko) |
CO (1) | CO5251381A1 (ko) |
CY (3) | CY1106357T1 (ko) |
CZ (1) | CZ20022093A3 (ko) |
DE (4) | DE60032823T2 (ko) |
DK (4) | DK1352896T3 (ko) |
EE (1) | EE05134B1 (ko) |
ES (4) | ES2215777T3 (ko) |
HK (2) | HK1057035A1 (ko) |
HU (1) | HUP0300616A3 (ko) |
IL (2) | IL150124A0 (ko) |
IS (1) | IS2246B (ko) |
MX (1) | MXPA02005789A (ko) |
MY (1) | MY125978A (ko) |
NO (1) | NO328682B1 (ko) |
NZ (1) | NZ519378A (ko) |
PL (1) | PL200836B1 (ko) |
PT (4) | PT1242364E (ko) |
SI (1) | SI1352895T1 (ko) |
SK (1) | SK286987B6 (ko) |
TR (1) | TR200401432T4 (ko) |
TW (1) | TWI258462B (ko) |
WO (1) | WO2001044170A1 (ko) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9904505D0 (sv) | 1999-12-09 | 1999-12-09 | Astra Pharma Prod | Novel compounds |
TWI258462B (en) * | 1999-12-17 | 2006-07-21 | Astrazeneca Ab | Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same |
SE9904738D0 (sv) | 1999-12-22 | 1999-12-22 | Astra Pharma Prod | Novel compounds |
PA8557501A1 (es) | 2001-11-12 | 2003-06-30 | Pfizer Prod Inc | Benzamida, heteroarilamida y amidas inversas |
WO2003042190A1 (en) | 2001-11-12 | 2003-05-22 | Pfizer Products Inc. | N-alkyl-adamantyl derivatives as p2x7-receptor antagonists |
SE0200920D0 (sv) * | 2002-03-25 | 2002-03-25 | Astrazeneca Ab | Novel compounds |
US7071223B1 (en) | 2002-12-31 | 2006-07-04 | Pfizer, Inc. | Benzamide inhibitors of the P2X7 receptor |
PA8591801A1 (es) | 2002-12-31 | 2004-07-26 | Pfizer Prod Inc | Inhibidores benzamidicos del receptor p2x7. |
SE0300445D0 (sv) * | 2003-02-18 | 2003-02-18 | Astrazeneca Ab | New combination |
SE0300480D0 (sv) * | 2003-02-21 | 2003-02-21 | Astrazeneca Ab | Novel compounds |
DE602004005033T2 (de) * | 2003-05-12 | 2007-08-09 | Pfizer Products Inc., Groton | Benzamidinhibitoren des p2x7-rezeptors |
US20070281931A1 (en) * | 2003-05-29 | 2007-12-06 | Nigel Boughton-Smith | Pharmaceutical Composition Containing a P2x7 Receptor Antagonist and Methotrexate |
BRPI0410739A (pt) * | 2003-05-29 | 2006-06-27 | Astrazeneca Ab | composição farmacêutica compreendendo um antagonista do receptor p2x7 e um fator de necrose tumoral (alfa) |
US20070010497A1 (en) * | 2003-05-29 | 2007-01-11 | Nigel Boughton-Smith | Pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine |
SE0302192D0 (sv) * | 2003-08-08 | 2003-08-08 | Astrazeneca Ab | Novel compounds |
SE0302488D0 (sv) * | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | New combination |
CA2572119A1 (en) * | 2004-06-29 | 2006-01-12 | Warner-Lambert Company Llc | Combination therapies utilizing benzamide inhibitors of the p2x7 receptor |
CA2571124A1 (en) * | 2004-06-29 | 2006-01-12 | Pfizer Products Inc. | Method for preparing 5-`4-(2-hydroxy-propyl)-3,5-dioxo-4,5-dihydro-3h`1,2,4!triazin-2-yl!-benzamide derivatives by deprotecting the hydroxyl-protected precursers |
SA05260265A (ar) * | 2004-08-30 | 2005-12-03 | استرازينيكا ايه بي | مركبات جديدة |
US20060063834A1 (en) * | 2004-09-09 | 2006-03-23 | Frangioni John V | Substituted adamantanes, and methods of making the same |
SE0402925D0 (sv) * | 2004-11-30 | 2004-11-30 | Astrazeneca Ab | Novel Compounds |
EP1906960A4 (en) * | 2005-07-11 | 2010-03-10 | Astrazeneca Ab | NEW COMBINATION 1 |
WO2007008157A1 (en) * | 2005-07-11 | 2007-01-18 | Astrazeneca Ab | New combination 2 |
TW200819416A (en) * | 2006-09-05 | 2008-05-01 | Astrazeneca Ab | Novel process 470 |
MX2010008577A (es) | 2008-02-06 | 2010-11-25 | Astrazeneca Ab | Compuestos. |
EA022505B1 (ru) | 2008-03-25 | 2016-01-29 | Эффектис Фармасьютиклз Аг | Новые p2x7r антагонисты и их применение |
PT2243772E (pt) | 2009-04-14 | 2012-03-28 | Affectis Pharmaceuticals Ag | Novos antagonistas de p2x7r e sua utilização |
GB2469915A (en) * | 2009-04-30 | 2010-11-03 | Astrazeneca Ab | 2-chloro-5-[3-[(3-hydroxypropyl)amino]propyl]-N-(tricyclo[3.3.1.13,7]dec- 1-ylmethyl)-benzamide hydrochloride salt |
GB0913342D0 (en) | 2009-07-31 | 2009-09-16 | Astrazeneca Ab | Compounds - 801 |
EP2322149A1 (en) | 2009-11-03 | 2011-05-18 | Universidad del Pais Vasco | Methods and compositions for the treatment of ischemia |
JP2013526496A (ja) | 2010-05-14 | 2013-06-24 | アフェクティス ファーマシューティカルズ アーゲー | P2x7r拮抗剤の新規調製方法 |
JP2013249256A (ja) * | 2010-09-15 | 2013-12-12 | Astellas Pharma Inc | 脂肪性肝疾患治療薬 |
WO2012110190A1 (en) | 2011-02-17 | 2012-08-23 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
WO2012163456A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
WO2012163792A1 (en) | 2011-05-27 | 2012-12-06 | Affectis Pharmaceuticals Ag | Novel p2x7r antagonists and their use |
KR101995088B1 (ko) | 2011-07-22 | 2019-07-02 | 이도르시아 파마슈티컬스 리미티드 | P2x7 수용체 길항제로서의 헤테로시클릭 아미드 유도체 |
JP6111268B2 (ja) | 2012-01-20 | 2017-04-05 | アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd | P2x7受容体アンタゴニストとしての複素環アミド誘導体 |
BR112015013463B1 (pt) | 2012-12-12 | 2022-06-14 | Idorsia Pharmaceuticals Ltd | Derivados de carboxamida indol como antagonistas do receptor de p2x7 |
ES2614495T3 (es) | 2012-12-18 | 2017-05-31 | Actelion Pharmaceuticals Ltd. | Derivados de indol carboxamida como antagonistas del receptor P2X7 |
KR102220847B1 (ko) | 2013-01-22 | 2021-02-26 | 이도르시아 파마슈티컬스 리미티드 | P2x7 수용체 길항제로서의 헤테로시클릭 아미드 유도체 |
ES2616114T3 (es) | 2013-01-22 | 2017-06-09 | Actelion Pharmaceuticals Ltd. | Derivados de amida heterocíclica como antagonistas del receptor P2X7 |
WO2023158601A2 (en) * | 2022-02-15 | 2023-08-24 | The Children's Medical Center Corporation | Compositions and methods relating to atp/p2x7r signaling inhibition |
EP4230196A1 (en) | 2022-02-21 | 2023-08-23 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of dystrophinopathies |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3029241A (en) * | 1962-04-10 | Phenylpbperazinylacyl anilines | ||
US3464998A (en) * | 1968-03-04 | 1969-09-02 | Searle & Co | Adamantyl esters and amides of pyridinecarboxylic acids |
US3732305A (en) * | 1970-03-03 | 1973-05-08 | Us Army | S-substituted thiosulfuric acid derivatives and preparation thereof |
US3789072A (en) * | 1970-04-22 | 1974-01-29 | Squibb & Sons Inc | Carboxamides |
FR2346011A1 (fr) | 1976-02-02 | 1977-10-28 | Orsymonde | Acetanilido-piperazines |
ZA825719B (en) | 1981-09-03 | 1983-06-29 | Recordati Chem Pharm | Alkanoylanilides |
CA2015473C (en) | 1989-04-28 | 1998-04-14 | Iwao Kinoshita | Triphenylmethane derivatives |
US6021024A (en) * | 1992-02-21 | 2000-02-01 | Kabushiki Kaisha Toshiba | Magnetic disk drive having a constant skew angle |
CA2091194A1 (en) | 1992-04-08 | 1993-10-09 | Richard D. Connell | 2-oxo-ethyl derivatives as immunosuppressants |
ES2125285T3 (es) | 1992-07-31 | 1999-03-01 | Bristol Myers Squibb Co | Derivados inhibidores de la reabsorcion de adenosina de difenil-oxazoles, tiazoles e imidazoles. |
NZ269827A (en) | 1993-08-10 | 1996-10-28 | Black James Foundation | (hetero)aryl gastin and cck receptor ligands having a carboxy group(or derivative) or two carboxy groups(or derivatives)on adjacent carbon atoms |
US5530018A (en) * | 1994-02-04 | 1996-06-25 | G. D. Searle & Co. | Meso-azanoradamantanes |
GB9409150D0 (en) | 1994-05-09 | 1994-06-29 | Black James Foundation | Cck and gastrin receptor ligands |
DE69530081T2 (de) | 1994-05-27 | 2003-12-24 | Black James Foundation | Gastrin- und cck-antagonisten |
EP0786997A4 (en) | 1994-10-27 | 1998-03-11 | Merck & Co Inc | MUSCARINE ANAGONISTS |
DE19608653A1 (de) | 1996-03-06 | 1997-09-11 | Thomae Gmbh Dr K | Pyrimido[5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
SE9704544D0 (sv) * | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
SE9704546D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
SE9704545D0 (sv) * | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
AU1903799A (en) * | 1997-12-05 | 1999-06-28 | Eisai Co. Ltd. | Compositions and methods for modulating the activity of fibroblast growth factor |
US6018089A (en) * | 1997-12-09 | 2000-01-25 | Shell Oil Company | Process for separating linear internal olefins from branched internal olefins |
WO1999031096A1 (en) | 1997-12-18 | 1999-06-24 | Shaman Pharmaceuticals, Inc. | Piperazine derivatives useful as hypoglycemic agents |
AU3985699A (en) | 1998-05-19 | 1999-12-06 | Centaur Pharmaceuticals, Inc. | Amide therapeutics for the treatment of inflammatory bowel disease |
AU774526B2 (en) * | 1999-04-09 | 2004-07-01 | Astrazeneca Ab | Adamantane derivatives |
SE9901875D0 (sv) | 1999-05-25 | 1999-05-25 | Astra Pharma Prod | Novel compounds |
SE9904505D0 (sv) | 1999-12-09 | 1999-12-09 | Astra Pharma Prod | Novel compounds |
TWI258462B (en) * | 1999-12-17 | 2006-07-21 | Astrazeneca Ab | Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same |
SE9904652D0 (sv) * | 1999-12-17 | 1999-12-17 | Astra Pharma Prod | Novel Compounds |
SE9904738D0 (sv) * | 1999-12-22 | 1999-12-22 | Astra Pharma Prod | Novel compounds |
GB0013737D0 (en) | 2000-06-07 | 2000-07-26 | Astrazeneca Ab | Novel compounds |
US6555451B1 (en) * | 2001-09-28 | 2003-04-29 | The United States Of America As Represented By The Secretary Of The Navy | Method for making shallow diffusion junctions in semiconductors using elemental doping |
SE0103836D0 (sv) | 2001-11-16 | 2001-11-16 | Astrazeneca Ab | Novel compounds |
SE0200920D0 (sv) | 2002-03-25 | 2002-03-25 | Astrazeneca Ab | Novel compounds |
SE0300480D0 (sv) | 2003-02-21 | 2003-02-21 | Astrazeneca Ab | Novel compounds |
SE0302488D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | New combination |
SA05260265A (ar) | 2004-08-30 | 2005-12-03 | استرازينيكا ايه بي | مركبات جديدة |
SE0402925D0 (sv) | 2004-11-30 | 2004-11-30 | Astrazeneca Ab | Novel Compounds |
-
2000
- 2000-12-04 TW TW089125761A patent/TWI258462B/zh not_active IP Right Cessation
- 2000-12-12 KR KR1020077000596A patent/KR20070012883A/ko not_active Application Discontinuation
- 2000-12-12 DE DE60032823T patent/DE60032823T2/de not_active Expired - Lifetime
- 2000-12-12 ES ES00986155T patent/ES2215777T3/es not_active Expired - Lifetime
- 2000-12-12 DK DK03013990T patent/DK1352896T3/da active
- 2000-12-12 HU HU0300616A patent/HUP0300616A3/hu unknown
- 2000-12-12 WO PCT/SE2000/002505 patent/WO2001044170A1/en active Application Filing
- 2000-12-12 DK DK03013991T patent/DK1352897T3/da active
- 2000-12-12 EP EP03013989A patent/EP1352895B1/en not_active Expired - Lifetime
- 2000-12-12 ES ES03013990T patent/ES2294219T3/es not_active Expired - Lifetime
- 2000-12-12 JP JP2001545259A patent/JP3710418B2/ja not_active Expired - Lifetime
- 2000-12-12 BR BRPI0016395A patent/BRPI0016395B8/pt not_active IP Right Cessation
- 2000-12-12 DK DK00986155T patent/DK1242364T3/da active
- 2000-12-12 PT PT00986155T patent/PT1242364E/pt unknown
- 2000-12-12 AT AT03013991T patent/ATE350364T1/de active
- 2000-12-12 EP EP03013990A patent/EP1352896B1/en not_active Expired - Lifetime
- 2000-12-12 US US10/149,549 patent/US6881754B2/en not_active Expired - Lifetime
- 2000-12-12 ES ES03013989T patent/ES2282546T3/es not_active Expired - Lifetime
- 2000-12-12 AU AU22444/01A patent/AU780506B2/en not_active Expired
- 2000-12-12 DE DE60034155T patent/DE60034155T2/de not_active Expired - Lifetime
- 2000-12-12 DE DE60036968T patent/DE60036968T2/de not_active Expired - Lifetime
- 2000-12-12 EP EP07014968A patent/EP1862451A1/en not_active Withdrawn
- 2000-12-12 CA CA2393352A patent/CA2393352C/en not_active Expired - Lifetime
- 2000-12-12 PT PT03013989T patent/PT1352895E/pt unknown
- 2000-12-12 KR KR1020027007702A patent/KR100710110B1/ko active IP Right Grant
- 2000-12-12 PT PT03013991T patent/PT1352897E/pt unknown
- 2000-12-12 SI SI200030950T patent/SI1352895T1/sl unknown
- 2000-12-12 EE EEP200200330A patent/EE05134B1/xx not_active IP Right Cessation
- 2000-12-12 PL PL355913A patent/PL200836B1/pl not_active IP Right Cessation
- 2000-12-12 IL IL15012400A patent/IL150124A0/xx not_active IP Right Cessation
- 2000-12-12 CN CNB008189226A patent/CN1312120C/zh not_active Expired - Lifetime
- 2000-12-12 TR TR2004/01432T patent/TR200401432T4/xx unknown
- 2000-12-12 CO CO00094336A patent/CO5251381A1/es not_active Application Discontinuation
- 2000-12-12 DK DK03013989T patent/DK1352895T3/da active
- 2000-12-12 PT PT03013990T patent/PT1352896E/pt unknown
- 2000-12-12 EP EP03013991A patent/EP1352897B1/en not_active Expired - Lifetime
- 2000-12-12 MX MXPA02005789A patent/MXPA02005789A/es active IP Right Grant
- 2000-12-12 DE DE60009147T patent/DE60009147T2/de not_active Expired - Lifetime
- 2000-12-12 SK SK841-2002A patent/SK286987B6/sk not_active IP Right Cessation
- 2000-12-12 AT AT03013990T patent/ATE376994T1/de active
- 2000-12-12 AT AT03013989T patent/ATE358117T1/de active
- 2000-12-12 AT AT00986155T patent/ATE261933T1/de active
- 2000-12-12 EP EP00986155A patent/EP1242364B1/en not_active Expired - Lifetime
- 2000-12-12 NZ NZ519378A patent/NZ519378A/en not_active IP Right Cessation
- 2000-12-12 CZ CZ20022093A patent/CZ20022093A3/cs unknown
- 2000-12-12 ES ES03013991T patent/ES2279031T3/es not_active Expired - Lifetime
- 2000-12-15 AR ARP000106695A patent/AR035325A1/es active IP Right Grant
- 2000-12-15 MY MYPI20005926A patent/MY125978A/en unknown
-
2002
- 2002-05-31 IS IS6406A patent/IS2246B/is unknown
- 2002-06-14 NO NO20022856A patent/NO328682B1/no not_active IP Right Cessation
- 2002-11-11 HK HK03109398A patent/HK1057035A1/xx not_active IP Right Cessation
- 2002-11-11 HK HK02108164.1A patent/HK1046678B/zh not_active IP Right Cessation
-
2004
- 2004-03-31 US US10/813,426 patent/US7132457B2/en not_active Expired - Lifetime
-
2005
- 2005-05-27 AU AU2005202321A patent/AU2005202321B2/en not_active Ceased
- 2005-06-03 JP JP2005163710A patent/JP2005320340A/ja active Pending
-
2006
- 2006-09-29 US US11/529,746 patent/US7297818B2/en not_active Expired - Fee Related
-
2007
- 2007-03-06 CY CY20071100312T patent/CY1106357T1/el unknown
- 2007-05-17 CY CY20071100671T patent/CY1106602T1/el unknown
- 2007-06-20 US US11/812,673 patent/US20080139636A1/en not_active Abandoned
- 2007-12-19 CY CY20071101609T patent/CY1107838T1/el unknown
-
2008
- 2008-02-25 IL IL189758A patent/IL189758A0/en not_active IP Right Cessation
- 2008-12-04 US US12/314,156 patent/US20090176853A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20020061646A (ko) | 아다만탄 유도체 | |
US6417218B1 (en) | Substituted imidazoles, their preparation and use | |
JP2001525406A (ja) | 新規な化合物 | |
JP2003516382A (ja) | アダマンタン誘導体 | |
KR20020086737A (ko) | 치료에 유용한 디페닐 에테르 화합물 | |
HU211517A9 (en) | 2-amino-1,2,3,4-tetrahydronaphthalene derivatives active on the cardiovascular system, processes for their preparation and pharmaceutical compositions containing them | |
KR100652451B1 (ko) | Ccr-3 수용체 길항제 v | |
RU2272025C2 (ru) | Производные адамантана, способы их получения, фармацевтическая композиция на их основе и способ ее получения, способы лечения ревматоидного артрита и хронического обструктивного заболевания легких | |
CA2385809A1 (en) | Alkylamide compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
A107 | Divisional application of patent | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130321 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20140320 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20160318 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20170410 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20180404 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20190409 Year of fee payment: 13 |